Apogee Therapeutics upsizes $420M public offering for atopic dermatitis, COPD, asthma development.
Apogee Therapeutics, Inc., a clinical-stage biotech firm, has announced the pricing of an upsized $420M underwritten public offering of 6.77M shares at $62/share. The offering is set to close on March 12, pending customary conditions. Proceeds will support the development of differentiated biologics for atopic dermatitis, COPD, asthma, and other inflammatory and immunology indications.
March 08, 2024
3 Articles